Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 172


Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.

Johnston TH, Lacoste AMB, Visanji NP, Lang AE, Fox SH, Brotchie JM.

Neuropharmacology. 2018 Jun 1. pii: S0028-3908(18)30270-3. doi: 10.1016/j.neuropharm.2018.05.035. [Epub ahead of print] Review.


A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.

Henrich MT, Geibl FF, Lee B, Chiu WH, Koprich JB, Brotchie JM, Timmermann L, Decher N, Matschke LA, Oertel WH.

Acta Neuropathol Commun. 2018 May 10;6(1):39. doi: 10.1186/s40478-018-0541-1.


Corrigendum to "Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism" [Neurobiol. Dis. 106 (2018) 133-146].

Gleave JA, Arathoon LR, Trinh D, Lizal KE, Giguère N, Barber JEM, Najarali Z, Hassan Khan M, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE.

Neurobiol Dis. 2018 Aug;116:180. doi: 10.1016/j.nbd.2018.02.018. Epub 2018 Mar 20. No abstract available.


DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.

Johnston TH, Versi E, Howson PA, Ravenscroft P, Fox SH, Hill MP, Reidenberg BE, Corey R, Brotchie JM.

Neuropharmacology. 2018 Mar 15;131:116-127. doi: 10.1016/j.neuropharm.2017.11.046. Epub 2017 Nov 29.


Reply to "Can STN DBS protect both nigral somata and innervation of the striatum?"

Koprich JB, Brotchie JM, Musacchio T, Volkmann J, Ip CW.

Ann Neurol. 2017 Nov;82(5):856. doi: 10.1002/ana.25066. Epub 2017 Oct 26. No abstract available.


Animal models of α-synucleinopathy for Parkinson disease drug development.

Koprich JB, Kalia LV, Brotchie JM.

Nat Rev Neurosci. 2017 Sep;18(9):515-529. doi: 10.1038/nrn.2017.75. Epub 2017 Jul 13. Review.


Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism.

Gleave JA, Arathoon LR, Trinh D, Lizal KE, Giguère N, Barber JHM, Najarali Z, Khan MH, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE.

Neurobiol Dis. 2017 Oct;106:133-146. doi: 10.1016/j.nbd.2017.06.009. Epub 2017 Jul 1. Erratum in: Neurobiol Dis. 2018 Mar 20;:.


Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model.

Musacchio T, Rebenstorff M, Fluri F, Brotchie JM, Volkmann J, Koprich JB, Ip CW.

Ann Neurol. 2017 Jun;81(6):825-836. doi: 10.1002/ana.24947. Epub 2017 Jun 9.


AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.

Ip CW, Klaus LC, Karikari AA, Visanji NP, Brotchie JM, Lang AE, Volkmann J, Koprich JB.

Acta Neuropathol Commun. 2017 Feb 1;5(1):11. doi: 10.1186/s40478-017-0416-x.


α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.

Visanji NP, Brotchie JM, Kalia LV, Koprich JB, Tandon A, Watts JC, Lang AE.

Trends Neurosci. 2016 Nov;39(11):750-762. doi: 10.1016/j.tins.2016.09.003. Epub 2016 Oct 21. Review.


Tor1a+/- mice develop dystonia-like movements via a striatal dopaminergic dysregulation triggered by peripheral nerve injury.

Ip CW, Isaias IU, Kusche-Tekin BB, Klein D, Groh J, O'Leary A, Knorr S, Higuchi T, Koprich JB, Brotchie JM, Toyka KV, Reif A, Volkmann J.

Acta Neuropathol Commun. 2016 Oct 3;4(1):108.


Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of Nonhuman Primate Studies and Clinical Trials.

Huot P, Fox SH, Brotchie JM.

J Pharmacol Exp Ther. 2016 Jun;357(3):562-9. doi: 10.1124/jpet.116.232371. Epub 2016 Apr 13. Review.


Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.

Ma Y, Johnston TH, Peng S, Zuo C, Koprich JB, Fox SH, Guan Y, Eidelberg D, Brotchie JM.

Mov Disord. 2015 Aug;30(9):1283-8. doi: 10.1002/mds.26302.


The link between mitochondrial complex I and brain-derived neurotrophic factor in SH-SY5Y cells--The potential of JNX1001 as a therapeutic agent.

Kim HK, Mendonça KM, Howson PA, Brotchie JM, Andreazza AC.

Eur J Pharmacol. 2015 Oct 5;764:379-84. doi: 10.1016/j.ejphar.2015.07.013. Epub 2015 Jul 8.


The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.

Huot P, Johnston TH, Fox SH, Newman-Tancredi A, Brotchie JM.

Neuropharmacology. 2015 Oct;97:306-11. doi: 10.1016/j.neuropharm.2015.05.033. Epub 2015 Jun 10.


Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.

He Q, Koprich JB, Wang Y, Yu WB, Xiao BG, Brotchie JM, Wang J.

Mol Neurobiol. 2016 May;53(4):2258-68. doi: 10.1007/s12035-015-9173-7. Epub 2015 May 14.


Monoamine reuptake inhibitors in Parkinson's disease.

Huot P, Fox SH, Brotchie JM.

Parkinsons Dis. 2015;2015:609428. doi: 10.1155/2015/609428. Epub 2015 Feb 25. Review.


Gap junction blockers attenuate beta oscillations and improve forelimb function in hemiparkinsonian rats.

Phookan S, Sutton AC, Walling I, Smith A, O'Connor KA, Campbell JC, Calos M, Yu W, Pilitsis JG, Brotchie JM, Shin DS.

Exp Neurol. 2015 Mar;265:160-70. doi: 10.1016/j.expneurol.2015.01.004. Epub 2015 Jan 23.


Management of impulse control disorders in Parkinson's disease: Controversies and future approaches.

Samuel M, Rodriguez-Oroz M, Antonini A, Brotchie JM, Ray Chaudhuri K, Brown RG, Galpern WR, Nirenberg MJ, Okun MS, Lang AE.

Mov Disord. 2015 Feb;30(2):150-9. doi: 10.1002/mds.26099. Epub 2015 Jan 21. Review.

Supplemental Content

Loading ...
Support Center